| 148.53 -1.03 (-0.69%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 178.73 | 1-year : | 185.87 |
| Resists | First : | 153.02 | Second : | 159.13 |
| Pivot price | 148.86  |
|||
| Supports | First : | 143.13 | Second : | 119.08 |
| MAs | MA(5) : | 148.17  |
MA(20) : | 150.94 |
| MA(100) : | 156.88 |
MA(250) : | 158.78 |
|
| MACD | MACD : | -2.5 |
Signal : | -2.7 |
| %K %D | K(14,3) : | 42.2 |
D(3) : | 36.6 |
| RSI | RSI(14): 39.5 |
|||
| 52-week | High : | 175.97 | Low : | 143.13 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ JNJ ] has closed above bottom band by 46.7%. Bollinger Bands are 25.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 149.11 - 149.86 | 149.86 - 150.35 |
| Low: | 145.04 - 146.05 | 146.05 - 146.7 |
| Close: | 147.07 - 148.61 | 148.61 - 149.58 |
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Wed, 24 Apr 2024
28 Years Later: Jodie Comer, Aaron Taylor-Johnson and Ralph Fiennes cast in sequel - The Guardian
Wed, 24 Apr 2024
Johnson calls on Columbia University president to resign during tense news conference - CNN
Wed, 24 Apr 2024
Bears stadium plan puts pressure on Brandon Johnson - Crain's Chicago Business
Wed, 24 Apr 2024
Columbia protests: Gov. Kathy Hochul tells Mike Johnson to go home - POLITICO
Wed, 24 Apr 2024
Cardinals T Paris Johnson Jr. and TE Trey McBride remember their emotions the night before they were drafted - AZCardinals.com
Wed, 24 Apr 2024
Ron Johnson’s line on security aid part of an unsettling pattern - MSNBC
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 2,410 (M) |
| Shares Float | 2,400 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 71.1 (%) |
| Shares Short | 15,940 (K) |
| Shares Short P.Month | 14,850 (K) |
| EPS | 7.42 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 28.56 |
| Profit Margin | 47.3 % |
| Operating Margin | 28.7 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -13.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 35.53 |
| EBITDA (p.s.) | 12.72 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 19.99 |
| PEG Ratio | 2.9 |
| Price to Book value | 5.19 |
| Price to Sales | 4.17 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|